Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 1487

Sort by

Sort Order Select

Journal Articles

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis

Mazyar Shadman, Jennifer R. Brown, Leyla Mohseninejad, Keri Yang, Heather Burnett, Binod Neupane, Rhys Williams, Nicole Lamanna, Susan M. O'Brien, Alessandra Tedeschi, Constantine S. Tam

Blood Adv (2025) 9 (12): 2863–2870.

https://doi.org/10.1182/bloodadvances.2024014523

Published: 2025

Includes: Supplemental data

Journal Articles

CD19.CAR T-cell–derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy

Blood Adv (2025) 9 (12): 2907–2919.

https://doi.org/10.1182/bloodadvances.2024014860

Published: 2025

Includes: Supplemental data

Journal Articles

Hematopoietic progenitor kinase-1 inhibition improves the in vitro efficacy of bispecific antibodies in CLL

Yamit Shorer Arbel, Liron Yitzhak, Ben-Zion Katz, Yair Herishanu

Blood Adv (2025) 9 (12): 2922–2926.

https://doi.org/10.1182/bloodadvances.2024015242

Published: 2025

Includes: Multimedia, Supplemental data

Journal Articles

Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi

Blood Adv (2025) 9 (12): 2927–2934.

https://doi.org/10.1182/bloodadvances.2024014790

Published: 2025

Includes: Supplemental data

Journal Articles

Spatial transcriptomics of progression gene signature and tumor microenvironment leading to progression in mycosis fungoides

Myoung Eun Choi, Gyeonghoon Kim, Hwa-Jeong Shin, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Woo Jin Lee

Blood Adv (2025) 9 (12): 2871–2885.

https://doi.org/10.1182/bloodadvances.2024014495

Published: 2025

Includes: Supplemental data

Journal Articles

The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential

Blood Adv (2025) 9 (12): 2953–2967.

https://doi.org/10.1182/bloodadvances.2025016180

Published: 2025

Includes: Supplemental data

Journal Articles

Binding of RHOA G17V to p300 enhances its HAT activity: a new mechanism of epigenetic deregulation in TFH lymphoma

David Vallois, Mélanie Juilland, Kalliopi Ioannidou, François Lemonnier, Edoardo Missiaglia, Bettina Bisig, Margot Thome, Laurence de Leval

Blood Adv (2025) 9 (12): 3031–3043.

https://doi.org/10.1182/bloodadvances.2024014671

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma

Joshua N. Gustine, Andrew R. Branagan, Diana D. Cirstea, Farah Rexha, Ryan Han, Andrew J. Yee, Marcela V. Maus, Matthew J. Frigault, Noopur S. Raje

Blood Adv (2025) 9 (12): 3026–3030.

https://doi.org/10.1182/bloodadvances.2025015981

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world Evidence of Duvelisib and Romidepsin in Relapsed/Refractory Peripheral and Cutaneous T-cell Lymphomas

Blood Adv bloodadvances.2025016347.

https://doi.org/10.1182/bloodadvances.2025016347

Published: 2025

Includes: Supplemental data

Journal Articles

Pralatrexate Is Effective in Cytotoxic Cutaneous T-cell Lymphomas

Christina Poh, Jenna M Voutsinas, Mazyar Shadman, Ryan C. Lynch, Edus H Warren, Caitlin A Crimp, Brian G Till, Chaitra S. Ujjani, Mengyang Di, Vikram Raghunathan, Stephen D Smith, Qian Vicky Wu, Michi M. Shinohara, Ajay K Gopal

Blood Adv bloodadvances.2025016680.

https://doi.org/10.1182/bloodadvances.2025016680

Published: 2025

Journal Articles

Peripheral Neuropathy and BTKis in Waldenström: A Response?

Chiara Briani, Bruno Ferrero, Alessandro Salvalaggio, Simone Ragaini, Enrico Amaducci, Irene Dogliotti, Andrea Visentin, Simone Ferrero

Blood Adv bloodadvances.2025016734.

https://doi.org/10.1182/bloodadvances.2025016734

Published: 2025

Journal Articles

BRCA1/2 impact on the development of implant-associated lymphoma in women with breast cancer and textured implants

Paola Ghione, Diana Mandelker, Maria E. Arcila, Venkatraman E Seshan, Mary Beth Terry, Vijai Joseph, Peter Gabriel Cordeiro, Chad Vanderbilt, Joyce C. Pressley, Alexander Chan, Natasha Galasso, Ahmet Dogan, Gilles A. Salles, Daphne de Jong, Flora E. van Leeuwen, Steven M Horwitz

Blood Adv bloodadvances.2025016810.

https://doi.org/10.1182/bloodadvances.2025016810

Published: 2025

Journal Articles

Familial Forms of Chronic Lymphocytic Leukemia Have a Worse Prognosis Than Sporadic Forms: an Italian Case-Control Study

Blood Adv bloodadvances.2025016546.

https://doi.org/10.1182/bloodadvances.2025016546

Published: 2025

Journal Articles

Expression of HERV-K and embryonic genes in chronic lymphocytic leukemia and their association with therapy regimens

Blood Adv bloodadvances.2024014181.

https://doi.org/10.1182/bloodadvances.2024014181

Published: 2025

Journal Articles

Extramedullary plasmacytoma in children is a genetically distinct localized neoplasia curable by surgical resection

Ilske Oschlies, Julia Richter, Amelie Alfert, Fernando Chahud, Stephanie Mueller, Ingrid Simonitsch-Klupp, Hannah von Mersi, Andishe Attarbaschi, Karoline Koch, Christoph Schaefers, Monika Brüggemann, Cecilia Bozzetti, Wilhelm Woessmann, Birgit Burkhardt, Wolfram Klapper

Blood Adv bloodadvances.2025016596.

https://doi.org/10.1182/bloodadvances.2025016596

Published: 2025

Includes: Supplemental data

Journal Articles

Blinatumomab Use in Pediatric B-ALL: Where are we now?

Anurekha G Hall, Rachel E Rau

Blood Adv bloodadvances.2024014043.

https://doi.org/10.1182/bloodadvances.2024014043

Published: 2025

Journal Articles

Thyroid hormones contribute to JAK/STAT pathway abnormal activation promoting T-cell lymphoma dissemination

María Mercedes Debernardi, Alejandro Correa, Lucero Alvarado, María V. Revuelta, Helena Andrea Sterle, Gonzalo Gonzalez, Ingrid Larissa Melo Souza, Jorgelina Nelly Real, Dra, María Teresa Garcia de Dávila, Johanna Abigail Diaz Albuja, Cinthia Rosemblit, Leandro Cerchietti, Graciela A Cremaschi, Florencia Cayrol

Blood Adv bloodadvances.2024015332.

https://doi.org/10.1182/bloodadvances.2024015332

Published: 2025

Includes: Supplemental data

Journal Articles

Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma

Alexey V Danilov, Swetha Thiruvengadam, Kim Linton, Karen Cumings, Viktor V Chirikov, Alex Mutebi, Savreet Bains Chawla, Anindit Chhibber, Fernando Rivas Navarro, Felipe Marques Gonçalves, Anthony Wang, Zhijie Ding, Abualbishr Alshreef, Elena Favaro, Daniela Hoehn, Anna Sureda

Blood Adv bloodadvances.2024015274.

https://doi.org/10.1182/bloodadvances.2024015274

Published: 2025

Includes: Supplemental data

Journal Articles

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia

Blood Adv (2025) 9 (11): 2808–2817.

https://doi.org/10.1182/bloodadvances.2025016006

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

Blood Adv (2025) 9 (11): 2763–2772.

https://doi.org/10.1182/bloodadvances.2024014846

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis

CD19.CAR T-cell–derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy

Hematopoietic progenitor kinase-1 inhibition improves the in vitro efficacy of bispecific antibodies in CLL

Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi

Spatial transcriptomics of progression gene signature and tumor microenvironment leading to progression in mycosis fungoides

The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential

Binding of RHOA G17V to p300 enhances its HAT activity: a new mechanism of epigenetic deregulation in TFH lymphoma

Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma

Real-world Evidence of Duvelisib and Romidepsin in Relapsed/Refractory Peripheral and Cutaneous T-cell Lymphomas

Pralatrexate Is Effective in Cytotoxic Cutaneous T-cell Lymphomas

Peripheral Neuropathy and BTKis in Waldenström: A Response?

BRCA1/2 impact on the development of implant-associated lymphoma in women with breast cancer and textured implants

Familial Forms of Chronic Lymphocytic Leukemia Have a Worse Prognosis Than Sporadic Forms: an Italian Case-Control Study

Expression of HERV-K and embryonic genes in chronic lymphocytic leukemia and their association with therapy regimens

Extramedullary plasmacytoma in children is a genetically distinct localized neoplasia curable by surgical resection

Blinatumomab Use in Pediatric B-ALL: Where are we now?

Thyroid hormones contribute to JAK/STAT pathway abnormal activation promoting T-cell lymphoma dissemination

Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only